摘要
A phase Ⅰ/Ⅱ clinical trial for treating malignant melanoma by boron neutron capture therapy(BNCT) was designed to evaluate whether the world's first in-hospital neutron irradiator(IHNI) was qualified for BNCT. In this clinical trial planning to enroll 30 patients, the first case was treated on August 19, 2014. We present the protocol of this clinical trial, the treating procedure, and the clinical outcome of this first case. Only grade 2 acute radiation injury was observed during the first four weeks after BNCT and the injury healed after treatment. No late radiation injury was found during the 24-month follow-up. Based on positron emission tomography-computed tomography(PET/CT) scan, pathological analysis and gross examination, the patient showed a complete response to BNCT,indicating that BNCT is a potent therapy against malignant melanoma and IHNI has the potential to enable the delivery of BNCT in hospitals.
A phase Ⅰ/Ⅱ clinical trial for treating malignant melanoma by boron neutron capture therapy(BNCT) was designed to evaluate whether the world's first in-hospital neutron irradiator(IHNI) was qualified for BNCT. In this clinical trial planning to enroll 30 patients, the first case was treated on August 19, 2014. We present the protocol of this clinical trial, the treating procedure, and the clinical outcome of this first case. Only grade 2 acute radiation injury was observed during the first four weeks after BNCT and the injury healed after treatment. No late radiation injury was found during the 24-month follow-up. Based on positron emission tomography-computed tomography(PET/CT) scan, pathological analysis and gross examination, the patient showed a complete response to BNCT,indicating that BNCT is a potent therapy against malignant melanoma and IHNI has the potential to enable the delivery of BNCT in hospitals.
基金
supported by the National Science&Technology Pillar Program during the 12th Five-Year Plan Period(No.2013BAI01B08)
the Major Program of the National Natural Science Foundation of China(No.51290295)